Regeneron Pharmaceuticals
stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.
This story was initially revealed on Healthcare Dive. To obtain every day information and insights, subscribe to our free every...
US President Donald Trump on Tuesday (native time) mentioned {that a} high-level assembly regarding the state of affairs in Gaza...
Senator Ted Cruz has grow to be essentially the most outstanding Republican to criticize Federal Communications Fee Chair Brendan Carr,...
Award acknowledges completed feminine leaders whose examples set a basis throughout all ranges of an organization’s provide chain community SAN...
This text was written byObserveThe fairness market is a robust mechanism as day by day fluctuations in value get aggregated...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
